Research programme: hypoxia inducible factor-proline dioxygenase inhibitors - Akebia Therapeutics
Alternative Names: AKB-6899; HIF-PH inhibitors - Akebia TherapeuticsLatest Information Update: 21 Mar 2023
At a glance
- Originator Akebia Therapeutics
- Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Small molecules
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute kidney injury; Retinopathy of prematurity
- Discontinued Cancer; Inflammatory bowel diseases
Most Recent Events
- 10 Mar 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 10 Mar 2023 Discontinued - Preclinical for Inflammatory bowel diseases in USA (unspecified route)
- 10 Mar 2023 Preclinical trials in Acute kidney injury and Retinopathy of prematurity in USA (unspecified route) as of March 2023